HeartFlow, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9.2M | 603 | 68.1% |
| Consulting Fee | $1.9M | 647 | 13.7% |
| Food and Beverage | $1.2M | 21,859 | 8.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $787,647 | 465 | 5.8% |
| Travel and Lodging | $296,831 | 1,080 | 2.2% |
| Education | $148,750 | 24 | 1.1% |
| Space rental or facility fees (teaching hospital only) | $21,000 | 10 | 0.2% |
| Grant | $13,000 | 4 | 0.1% |
| Entertainment | $654.34 | 7 | 0.0% |
| Honoraria | $249.80 | 4 | 0.0% |
| Gift | $83.55 | 1 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care | $3.2M | 0 | 133 |
| 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 424 PRECISE | $2.0M | 0 | 187 |
| 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 438 JACS | $890,682 | 0 | 29 |
| Prospective Randomized Trial of Optimal Evaluation of Suspected Coronary Artery Disease | $654,643 | 0 | 5 |
| RetrospectivE study of FFRCT compared to mFFR and CTA In the post-market ENvironmEnt | $356,268 | 0 | 8 |
| Precise Study | $267,144 | 0 | 32 |
| Evaluation of FFRCT to improve efficacy and efficiency of management of Patients With Acute Chest Pain as compared to anatomic CCTA and Standard of Care | $245,460 | 0 | 3 |
| 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 447 REVEALPLAQUE | $184,335 | 0 | 21 |
| REFINE Cardiovascular Imaging Core Lab. | $183,688 | 0 | 1 |
| 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 448 MGH Type 2 MI | $168,551 | 0 | 6 |
| PRECISE, C6000136 Protocol #CP-907-001-A PI: Victor Marinnescu, MD | $160,300 | 0 | 7 |
| AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management (DECIDE) | $114,550 | 0 | 17 |
| PRECISE, C6000148 Protocol #CP-907-001-A PI: Sorin Danciu, MD, | $102,250 | 0 | 1 |
| Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization (PRECISE) | $95,895 | 0 | 21 |
| Promise - CT - FFR Cost Effectiveness Analysis | $89,560 | 0 | 1 |
| SPECT vs CT vs. FFRCT: Diagnostic accuracy (using FFRCT as gold standard) | $78,576 | 0 | 4 |
| 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 437 P3 | $69,500 | 0 | 1 |
| 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 442 FFRct ACP | $64,800 | 0 | 2 |
| 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 443 ADVANCE-ED | $52,640 | 0 | 8 |
| "The AFFECTS Study: Assessment of Fractional Flow reservE Computed Tomography versus Single photon emission computed tomography in the diagnosis of hemodynamically significant coronary artery disease " | $46,464 | 0 | 5 |
| The AFFECTS Study: Assessment of Fractional Flow reservE Computed Tomography versus | $42,079 | 0 | 5 |
| 100 Analysis : 200 FFRct Analysis : 201 FFRct (Default) | $30,150 | 0 | 2 |
| PRECISE, C6000136 Protocol #CP-907-001-A PI: Victor Marinescu, MD, | $29,550 | 0 | 3 |
| Assessing Diagnostic Value of Non-invasive FFRCT in Coronary CarE | $12,848 | 0 | 3 |
| PRECISE CP-907-001-A - IRB FEE | $12,500 | 0 | 1 |
| Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularizaton -Protocol CP-907-001-A | $12,094 | 0 | 3 |
| PRECISE Protocol #CP-907-001-A | $11,000 | 0 | 1 |
| Precise Study -CP-907-001-A | $7,813 | 0 | 2 |
| CP-907-001-A PRECISE | $7,700 | 0 | 1 |
| PRECISE CP-907-001-A | $6,350 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Shone Almeida, Md, MD | Cardiovascular Disease | Tampa, FL | $9,502 | $0 |
| Jagat P Narula, Md, MD | Cardiovascular Disease | Houston, TX | $9,444 | $0 |
| Andrew Zurick, M.d, M.D | Hospitalist | Nashville, TN | $9,289 | $0 |
| Dr. Mahesh Chandrasekhar, M.d, M.D | Internal Medicine | Winston Salem, NC | $9,272 | $0 |
| Mr. Ismael Lopez, Pa, PA | Physician Assistant | Harlingen, TX | $9,019 | $0 |
| Venkateshwar Polsani, Md, MD | Internal Medicine | Atlanta, GA | $8,568 | $0 |
| Michelle Kelsey, M.d, M.D | Student in an Organized Health Care Education/Training Program | Boston, MA | $8,080 | $0 |
| Dr. Yazan Daaboul, M.d, M.D | Internal Medicine | Cynthiana, KY | $8,013 | $0 |
| Esosa Odigie-Okon, Md, MD | Cardiovascular Disease | Fort Wayne, IN | $7,758 | $0 |
| Maros Ferencik, Md, MD | Internal Medicine | Portland, OR | $7,714 | $0 |
| Dr. Carlos Leon, Md, MD | Cardiovascular Disease | Orange Park, FL | $7,540 | $0 |
| Robert Safian, Md, MD | Cardiovascular Disease | Royal Oak, MI | $6,785 | $0 |
| James Udelson, M.d, M.D | Cardiovascular Disease | Boston, MA | $6,692 | $0 |
| Peter Monteleone, Md, MD | Interventional Cardiology | Kyle, TX | $6,484 | $0 |
| Dr. Quynh Truong, Md, MD | Internal Medicine | New York, NY | $6,380 | $0 |
| Christopher Schumann, M.d, M.D | Internal Medicine | Greensboro, NC | $6,199 | $0 |
| Dr. Benjamin Benson, Md, MD | Diagnostic Radiology | Gilbert, AZ | $6,074 | $0 |
| Kavitha Chinnaiyan, M.d, M.D | Cardiovascular Disease | Royal Oak, MI | $5,952 | $0 |
| Joao Cavalcante, Md, MD | Cardiovascular Disease | Minneapolis, MN | $5,733 | $0 |
| Dr. Michael Nanna, Md, Mhs, MD, MHS | Internal Medicine | New Haven, CT | $5,694 | $0 |
| Dr. James Januzzi, Md, MD | Internal Medicine | Boston, MA | $4,800 | $0 |
| Hiram Bezerra, Md, MD | Cardiovascular Disease | Tampa, FL | $4,642 | $0 |
| Mehran Moussavian, Do, DO | Cardiovascular Disease | Chula Vista, CA | $4,113 | $0 |
| Dr. Mark Finch, M.d, M.D | Nuclear Cardiology | Cherry Hill, NJ | $4,016 | $0 |
| Michael Kim, M.d, M.D | Interventional Cardiology | Manhasset, NY | $3,942 | $0 |
About HeartFlow, Inc.
HeartFlow, Inc. has made $13.5M in payments to 9,758 healthcare providers, recorded across 24,704 transactions in the CMS Open Payments database. In 2024, the company paid $1.9M. The top product by payment volume is FFRct ($9.1M).
Payments were distributed across 126 medical specialties. The top specialty by payment amount is Cardiovascular Disease ($2.2M to 3,323 doctors).
Payment categories include: Food & Beverage ($1.2M), Consulting ($1.9M), Research ($9.2M), Travel & Lodging ($296,831).
HeartFlow, Inc. is associated with 1 products in the CMS Open Payments database.